SCHEMBL13828360

SCHEMBL13828360

Cn1ncc2c(N3CCOCC3)nc(O)nc21

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
PDE10A Q9Y233 1/20 0.49
HRH1 P35367 1/20 0.49
HRH4 Q9H3N8 1/20 0.49
EIF2AK2 P19525 1/20 0.47
HTR2C P28335 1/20 0.46
NSD2 O96028 1/20 0.43
PKM P14618 1/20 0.43
RAF1 P04049 1/20 0.42
BRAF P15056 1/20 0.42
PIK3CA P42336 7/20 0.41
MTOR P42345 6/20 0.41
MAPT P10636 4/20 0.40
TP53 P04637 1/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 1/20 0.39
PIK3CG P48736 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13828369 0.85 HRH1 (0.66) MEN1KMT2AHRH1HRH4HTR2C
SCHEMBL12264971 0.84 MEN1 (0.63) MEN1KMT2APDE10AHRH1HRH4
SCHEMBL19119327 0.84 HRH1 (0.68) MEN1KMT2APDE10AHRH1HRH4
SCHEMBL12264967 0.83 KMT2A (0.62) MEN1KMT2APDE10AHRH1HRH4
SCHEMBL13828373 0.83 MEN1 (0.62) MEN1KMT2APDE10AHRH1HRH4
SCHEMBL13828335 0.83 MEN1 (0.62) MEN1KMT2APDE10AHRH1HRH4
SCHEMBL23200413 0.81 PIK3CA (0.57) MEN1KMT2APDE10APIK3CAMTOR
SCHEMBL19118709 0.81 HRH1 (0.76) MEN1KMT2APDE10AHRH1HRH4
SCHEMBL19119251 0.80 HRH4 (0.78) MEN1KMT2APDE10AHRH1HRH4
SCHEMBL24956779 0.80 KMT2A (0.58) MEN1KMT2APDE10AHRH1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2015-11-12 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB MEN1 4440/4885KMT2A 3362/4885PDE10A 877/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB MEN1 4440/4885KMT2A 3362/4885PDE10A 877/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB MEN1 4440/4885KMT2A 3362/4885PDE10A 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.